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Abstract
Background and objective: Collagen protein, which is abundant in the cornea and has a triple helix form, may be found
in almost every tissue matrix in the body. Natural cross connections between monomers provide the robustness of the
helical protein structure. Wollensak and his colleagues developed the Dresden Protocol, a keratoconus treatment based
on Corneal Cross-Linkage. We aimed to analyse and present the ﬁndings in individuals with progressive keratoconus
using topographic and refractive results after corneal collagen crosslinking treatment (CXL) (KC) after 3 months.
Methods: The study comprises a total of 100 patients who were diagnosed with progressive KC and who underwent
CXL between 2021 and 2022 at KRL Hospital Islamabad, Pakistan. All eyes in this study had a preoperative topography
within 1 month before CXL treatment and the follow-ups were conducted at 3 months interval.
Results: In our investigation, 100 patients were added. The average age was 24.74 years. 77% of the patients were
between the ages of 12 and 25 years, while 23% were between the ages of 26 and 50 years. In our survey, males made up
84% of the population, while females made up only 16%. The right eye was afﬂicted in 60% of cases, whereas the left eye
was impacted in 40% of the population. Grade 2 Keratoconus affected 42% of patients, whereas Grade 1 Keratoconus
affected 18%. Our ﬁndings were skewed toward men and the 12e25 age group, however in our recent study, we
discovered considerable KC stability 3 months after CXL.
Conclusion: Keratometric readings and visual acuity were stabilised or improved with CXL treatment. Keratoconus
stability can be reached 3 months following the treatment, according to our ﬁndings.
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1. Introduction

T

he term KERATOCONUS has a Greek derivation, with “Kerato” meaning “Cornea” and
“Conus” meaning “Cone Shaped.” As a result,
Keratoconus means “Cone Shaped Cornea.".1 Keratoconus affects 1 out of every 2000 persons on the
planet.1,2 Its annual incidence rates in Asian and
white populations are 25/100,000 and 3.3/100,000,
respectively; 10% of those afﬂicted have a positive
family history.1,3
Keratoconus is a non-inﬂammatory chronic ectatic
corneal condition that affects both eyes of the patient, producing impaired vision, myopia, and

uneven astigmatism, as well as scar development.4
Marc Amsler proposed the Amsler-Krumeich (AK)
Grading Technique in 1947 as a system for properly
grading illness degrees.5
Collagen protein, which has a triple helix shape
and is plentiful in the cornea, is found in practically
every tissue matrix in the body. The helical protein
structure's strength is ensured by natural cross
connections between the monomers. This can be
accomplished using the enzyme lysyl oxidase or
without enzymes through a process known as glycation, which occurs naturally as people age. UV
exposure causes oxidation, which releases reactive
oxygen species, which converts collagen monomers
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to cross linked polymers, making them stronger.6 In
2003, Wollensak and his colleagues at The University of Dresden devised a therapy for keratoconus
dubbed the Dresden Protocol, which was based on
Corneal Cross-Linkage treatment (CXL).7 The procedure was approved by the FDA in the United
States in 2016 as the gold standard treatment for
Keratoconus.6 Under aseptic conditions and with
adequate pain relief, the central 7e9 mm corneal
epithelium is removed, and a solution containing
0.1% riboﬂavin, 10 ml of 20% dextran, and 10 mg of
riboﬂavin-5-phosphate is applied for half an hour,
followed by exposure to 370 nm UVA at an irradiance of 3mW/cm2 for another half hour.2,7
Keratometry analyses the centermost 3 mm curvature of the front of the cornea on two axes, one
with the maximum corneal power and one with the
lowest, which are referred to as K values.8 K values
are measured in Dioptres ‘D’ mean value is
44.7080 ± 1.3343 D.8 Kmax is the steepest anterior
corneal curve power and is widely used to aid in the
diagnosis of corneal shape change, particularly
keratoconus.9 Kmax is also frequently used to assess
the efﬁciency of corneal cross-linking.9
This is assessed using the Galilei G6 Lens Professional (Ziemer Ophthalmic Systems AG, Port,
Switzerland), a novel anterior segment imaging
technology that incorporates a twin rotating
Scheimpﬂung camera, a placido disc topographer,
and an optical coherence tomography-based scan.10
A placido disc analyses light reﬂected off the anterior corneal surface as concentric rings, recording its
shape.11 A dual rotating Scheimpﬂung camera is a
spinning camera that generates a 3D picture of the
cornea by directing slit-shaped light beams at
different angles across the cornea.11
The purpose of this study is to add to Pakistan's
population-based data demonstrating corneal crosslinkage is a safe, ﬁnancially acceptable, effective
therapy with promising results for keratoconus patients. This treatment's research will also show better visual function and patient satisfaction.
A review of the literature revealed that the abovementioned therapy is beneﬁcial; Latif et al. found a
mean post-corneal cross-linkage decrease of 0.7D in
Kmax in all 25 patients in his research.12 Karaca
et al. observed a mean decrease in Kmax of 0.51D in
group one and 0.52D in group two of his 40 patients
treated with corneal cross-linkage.13 In a Brazilian
research, Kmax values were reduced by 0.68D
following corneal cross-linkage in all 75 patients
after three months and 0.87D after one year of
therapy.14 Another research in the Netherlands
found that following corneal cross-linkage treatment, Kmax was reduced by 1D in 102 eyes in 79

patients.15 In addition, a research in Egypt found
that corneal cross-linkage treatment reduced Kmax
by 1.57D in 40 keratoconus patients.16 AlQahtani
et al. reported in his study on 24 keratonconus patients that there was a mean stabilization of the
Kmax after corneal cross-linkage.2
The Amsler-Krumeich Grading System: is as follows: patients are considered to be Grade 1 if Mean
Keratometry (meanK) is < 48 D, Corneal Thickness
is > 500 microns, the Spherical Equivalent (SE) is < 5D and there are No Central Corneal Scars; Grade 2
if meanK is 48e53D, Corneal Thickness is 400e500
microns, SE is 5 to -8D and No Central Corneal
Scars; Grade 3 if meanK is 54e55D, Corneal Thickness is 200e400 microns, SE is > -8D and No Central
Corneal Scars; and ﬁnally Grade 4 if meanK
is > 55D, Corneal Thickness is < 200 microns, SE
cannot be measured and there are Corneal Scars.4

2. Materials and methods
This prospective experimental study was conducted at the Ophthalmology OPD of the KRL
Hospital, Islamabad, Pakistan between 2021 and
2022. Sample size of 100 was calculated by WHO
calculator keeping anticipated population proportion of 25%, absolute precision 5%, conﬁdence interval of 95%.
2.1. Inclusion & exclusion criteria
Inclusion criteria was determined to be any patient who falls in the ﬁrst 3 grades of the AK
(Amsler-Krumeich) Grading System after an initial
assessment of extensive slit-lamp examination by a
professional ophthalmologist. Only individuals
with KC grade 3 had thickness values of less than
400 m at the narrowest location were included in
the study.
An increase in the maximal keratometry (Kmax)
value of at least 0.75 diopter (D) and/or an increase
in the manifest cylinder of at least 0.75 D for at least
two consecutive measures in the previous 1 year at a
6-month interval was used to diagnose KC
progression.
Patients with a history of dry eye, eyelid abnormalities, meibomitis, blepharitis, and corneal scarring were excluded altogether from the study.
Patients with uveitis, cataracts, glaucoma, or any
history of such diseases were also excluded. Exclusion criteria also comprised of pregnant mothers or
mothers who were lactating.
The Amsler-Krumeich Grading System: is as follows: patients are considered to be Grade 1 if Mean
Keratometry (meanK) is < 48 D, Corneal Thickness

is > 500 microns, the Spherical Equivalent (SE) is < 5D and there are No Central Corneal Scars; Grade 2
if meanK is 48e53D, Corneal Thickness is 400e500
microns, SE is 5 to -8D and No Central Corneal
Scars; Grade 3 if meanK is 54e55D, Corneal Thickness is 200e400 microns, SE is > -8D and No Central
Corneal Scars; and ﬁnally Grade 4 if meanK
is > 55D, Corneal Thickness is < 200 microns, SE
cannot be measured and there are Corneal Scars.4
2.2. Data collection
Data collection for the study was done by after
ethical approval from the IRB committee. A detailed
history from the patient & detailed ocular examination and evaluation of the patient was carried out
by a senior ophthalmologist. Patient falling into the
criteria of keratoconus, informed consent was taken
from the patient.
Corneal Topographical scans was taken by a senior optometrist with The Galilei G6 Lens Professional (Ziemer Ophthalmic Systems AG, Port,
Switzerland) and data was recorded in the performa
of every patient before and 3 months after Corneal
Cross-Linkage treatment. The Galilei Analysis software which is an inbuilt software in The Galilei G6
Lens Professional (Ziemer Ophthalmic Systems AG,
Port, Switzerland) is used to calculate the Kmax.
2.3. Data analysis
Statistical analysis was performed using the Statistical Package IBM SPSS Statistics 26. Categorical
variables (i.e. gender, stage of keratoconus) will be
presented as frequency/percentage. The quantitative variables (i.e., age, Kmax) will be presented as
mean.
Each variable will be compared at different times
for sample at time of treatment and follow up, to
appreciate the progression of disease. Chi-square
test was applied & P value of <0.05 will be considered statistically signiﬁcant. Odds Ratio was calculated to check the risk of disease occurrence.

3. Results
One hundred patients were added in our study.
Mean age was 24.74 years.
77% of the patients were from 12 to 25 years age
group whereas 23% were from 26 to 50 years age
group. There were 84% male population in our
study whereas females were only 16%, as described
in Table 1.
60% patients had their right eye affected whereas
40% had their left eye affected. 67% patients

presented to the hospital after 1 year of diagnosis &
only 33% presented as early as within 6 months of
diagnosis to the hospital, as described in Table 2.
42% patients had Grade 2 Keratoconus, whereas
18% patients had Grade 1 Keratoconus, as described
in Table 3.
Mean Pre-Corneal K max was 54.885 whereas Post
Corneal k max mean was 53.826. Risk of Pre-corneal
K Max with respect to gender is 0.733 whereas Post
Corneal risk has decreased to 0.644 having p value
of 0.00. Pre-Corneal K Max has a risk of 2.353 to
occur with respect to age whereas Post-Corneal K
max has a risk of 1.719 having signiﬁcant p value, as
described in Table 4.

4. Discussions
Over the last decade, new and better KC therapies
have been presented, with the goal of signiﬁcantly
lowering transplantation rates and stopping disease
progression. Spoerl et al. were the ﬁrst to evaluate
the effects of a combination of riboﬂavin, a photosensitizer, with UV radiation in laboratory tests.
Both pig and human corneas showed an increase in
corneal stiffness in vitro.7 Wollensak et al. then
performed the ﬁrst pilot clinical trial in Dresden. At
follow-ups ranging from 3 to 47 months, KC progression was stopped in all 23 treated eyes. Kmax
was reduced by 2.01 D on average in 16 eyes,
refraction error was reduced by 1.14 D, and visual
acuity improved in 15 of 22 eyes. The major ﬁndings
of the study demonstrated a substantial drop in the
mean value of post corneal K-max for 100 eyes
included in the trial over a period of three months.
Similarly, there was a lowered incidence of postcorneal Kmax (OR: 0.644, 95% CI, OR; 1.719, 95% CI)
for both age and gender correspondingly. The data
supported the demonstration of a favorable prognosis following corneal collagen cross-linking with
riboﬂavin and ultraviolet A (UV-A) light in
reversing keratoconus.7
The results of the study match those of Tiveron
et al. in terms of achieving stability or achieving
decrease in keratoconus incident following CXL
treatment. However, they were unable to identify
any statistically signiﬁcant variation in keratometric
Table 1. Patient demographics.
Age
Gender
Total

12e25
26e50
Male
Female
119

Frequency

Percent

77
23
84
16
100.0

77.0
23.0
84.0
16.0
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Table 2. Showing frequency of effected eye & time since diagnosis.
Effected Eye
Time Since Diagnosis

Right
Left
6 months
1 year

Frequency

Percent

60
40
33
67

60.0
40.0
33.0
67.0

Table 3. Grade of keratoconus.
Grade 1
Grade 2
Grade 3

Frequency

Percent

18
42
40

18.0
42.0
40.0

readings between male and female patients
following CXL treatment. Whereas all the outcomes
were statistically signiﬁcant in our situation. Moreover, our results were skewed towards the male
gender and towards the age group of 12e25 years.
Furthermore, there was inadequate involvement of
female gender in the study. A retrospective study by
Kim et al. has indicated that the corneal epithelial
thickness is impacted by gender and found to be
greater among male children than female children.1
Studies have demonstrated a decline in corneal
thickness with an increase in the age of the patients
(2e4). There's a substantial correlation of total
corneal thickness with keratoconus owing to alterations in stromal and epithelial thickness.5 The
gender difference can be explained on the basis of
hormonal changes where females have 2e3 mm
thinner corneas than males. The actual cause behind
this is still uncertain6. These researches can give a
plausible explanation for our ﬁndings.
Overall, the results proved and recommended the
usefulness of CXL in the treatment of keratoconus.
We found signiﬁcant stability of KC 3 months
following CXL in our current investigation. A systematic study by Kobashi et al. reported a reduction
in Kmax value following CXL treatment for keratoconus during a follow-up period of one year.7
However, there's not adequate substantiation free of
considerable variation to sustain this agreement.
The review is scarce and indicates the necessity of a
randomized controlled experiment with a larger

sample size and less clinical variety in order to
produce useful and substantial ﬁndings.
Keratoconus is a degenerative illness that decreases vision and, in rare situations, cannot be cured
readily with normal therapies. Keratoconus generally
begins in the second decade of life, at adolescence,
and lasts until the fourth decade, when it stabilizes.
Corneal thinning produces irregular astigmatism,
myopia, and conical protrusion, leading in mild to
severe vision impairment and a detrimental impact
on the patient's quality of life. The development of
CXL treatment as a one-of-a-kind therapy for keratoconus was regarded as a watershed point in the
disease's treatment. However, even two decades after
CXL treatment's conception, there are still some
unsolved questions.8 While several studies have
looked into the effectiveness and safety of CXL,
certain studies have connected it to certain concerns,
including fungal and microbial infections and
corneal damage.9e11 Although these investigations
mostly consisted of case reports, other research has
shown signiﬁcant evidence that the safety of CXL
treatment is dependent on the techniques utilized
during the operation, such as the use of a light source
with uniform irradiance at a wavelength of 370 nm,
the removal of the epithelium to allow the diffusion
of the riboﬂavin, which is applied 30 min before UV
exposure, and a minimum corneal stroma thickness
of 400 mm.12e15
Appropriate patient selection is recognized as a
signiﬁcant element that can impact CXL treatment's
complications and failure rates. Patients over the age
of 35 are regarded to be at a larger risk of issues, as the
term suggests.16 The majority of the patients in the
study were from the age group of 12e25 years.
Furthermore, the time period between the performance of the operation and diagnosis was one year
for the majority of the patients, which could've
introduced a possible selection bias among the results
and can be regarded as a limitation of our ﬁndings.
The authors would like to note additional limitations of the study, such as the restricted sample size
and lack of female gender representation. Furthermore, the three-month follow-up time may be

Table 4. Showing the risk estimate & conﬁdence interval.

Pre- Corneal K Max with Gender
Pre- Corneal K Max with Age
Post- Corneal K Max with Gender
Post- Corneal K Max with Age

Odds ratio

95% Conﬁdence Interval
Lower

Upper

0.733
2.353
0.644
1.719

0.630
1.641
0.519
1.374

0.854
3.374
0.801
2.150

P Value

0.00
0.00
0.00
0.00

insufﬁcient to determine the procedure's effectiveness. Because the bulk of the sample was male and
the age group varied from 18 to 25 years, these
variables may have had an inﬂuence on the outcomes. To corroborate the ﬁndings, a randomized
experiment with a higher sample size and a longer
follow-up time is essential. It would offer a better
idea regarding the procedure's effectiveness.

5. Conclusions
As a result of the CXL treatment, the cornea takes
on a more regular shape without affecting the
corneal endothelium. We observed promising results of CXL treatment. Compared to other studies
our study found signiﬁcant differences in keratometric readings between male and female patients
after CXL treatment. We found signiﬁcant stability
of KC 3 months following CXL treatment in our
current investigation. Furthermore, our ﬁndings
were biased towards the male gender and the age
category of 12e25. Moreover, after this effective and
safe procedure, we recommend longer follow-up
periods and inclusion of more age groups.
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